Literature DB >> 11341599

Research on the best chemohyperthermia technique of treatment of peritoneal carcinomatosis after complete resection.

D Elias1, S Antoun, A Goharin, A E Otmany, J M Puizillout, P Lasser.   

Abstract

BACKGROUND: The complete or almost complete resection of peritoneal carcinomatosis (PC) followed by intraperitoneal chemohyperthermia (IPCH) is potentially capable of curing some patients presenting with disease confined to the peritoneum. AIMS: The aim of this prospective phase I-II study was to develop an efficient IPCH procedure with good thermal homogeneity and good spatial diffusion, that would be reproducible (and thus could be standardized and exported), and to evaluate patient tolerance and its efficiency in eradicating tumor tissue.
METHODS: Seven IPCH procedures were tested successively in 32 patients (up to a total of 35 IPCH). Each procedure was tested in at least 4 patients before modifications for technical reasons or due to inacceptable tolerance. Five of them were followed by early postoperative intraperitoneal chemotherapy (EPIC) lasting 4 days. Thermal homogeneity was measured with 6 thermal probes placed in different positions inside the abdominal cavity. Spatial diffusion was studied in the last patients by adding methylene blue to the IPCH liquid. The mean follow-up was 23.85 months for the series.
RESULTS: From the technological point of view, we have progressively shown that procedures with closure of the abdomen are not satisfactory: it was impossible to obtain thermal homogeneity when the entire parietal wound was closed, but markedly improved when only the skin was closed. However, these "closed" procedures did not allow us to treat all surfaces at risk. The peritoneal cavity "expander" did not permit treatment of the parietal wound and an indeterminate amount of the perfusion oozed out at its periphery. The open technique with traction of the skin upwards was superior. Using different procedures successively undermined the quality of the postoperative results. Three patients (8.6%) died and morbidity (albeit minimal) occurred in 27 patients (77%) during the postoperative course. Mortality and morbidity were significantly correlated (P = 0.02) with the peritoneal index (scoring the extent of PC). The 2-year survival rate was 60% and PC did not recur in 49% of the patients. The survival rate was correlated with the extent of PC (peritoneal index greater than or below 15) (P = 0.004), and with the absence of extraperitoneal disease (P = 0.01).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11341599

Source DB:  PubMed          Journal:  Int J Surg Investig        ISSN: 1028-5229


  20 in total

1.  Different mitochondrial response to cisplatin and hyperthermia treatment in human AGS, Caco-2 and T3M4 cancer cell lines.

Authors:  Sonata Trumbeckaite; Vaidotas Cesna; Aldona Jasukaitiene; Rasa Baniene; Antanas Gulbinas
Journal:  J Bioenerg Biomembr       Date:  2018-06-25       Impact factor: 2.945

2.  Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Methodology, Drugs and Bidirectional Chemotherapy.

Authors:  S J Valle; N A Alzahrani; W Liauw; P H Sugarbaker; A Bhatt; D L Morris
Journal:  Indian J Surg Oncol       Date:  2016-02-05

3.  HIPEC Methodology and Regimens: The Need for an Expert Consensus.

Authors:  Aditi Bhatt; Ignace de Hingh; Kurt Van Der Speeten; Martin Hubner; Marcello Deraco; Naoual Bakrin; Laurent Villeneuve; Shigeki Kusamura; Olivier Glehen
Journal:  Ann Surg Oncol       Date:  2021-06-17       Impact factor: 5.344

4.  Cytoreductive surgery combined with intraperitoneal chemohyperthermia for the treatment of advanced colon cancer.

Authors:  Claudio Zanon; Massimiliano Bortolini; Isabella Chiappino; Paolo Simone; Francesco Bruno; Piero Gaglia; Mario Airoldi; Leonorda Deriu; Alon Mashiah
Journal:  World J Surg       Date:  2006-11       Impact factor: 3.352

5.  Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer.

Authors:  Claudio Zanon; Renzo Clara; Isabella Chiappino; Massimiliano Bortolini; Silvia Cornaglia; Paolo Simone; Francesco Bruno; Leonarda De Riu; Mario Airoldi; Fulvia Pedani
Journal:  World J Surg       Date:  2004-09-29       Impact factor: 3.352

6.  Prospective randomized trial evaluating mandatory second look surgery with HIPEC and CRS vs. standard of care in patients at high risk of developing colorectal peritoneal metastases.

Authors:  Robert T Ripley; Jeremy L Davis; Clinton D Kemp; Seth M Steinberg; Mary Ann Toomey; Itzhak Avital
Journal:  Trials       Date:  2010-05-25       Impact factor: 2.279

7.  Multimodality treatment of peritoneal carcinomatosis from colorectal cancer: first results of a new German centre for peritoneal surface malignancies.

Authors:  P Piso; M H Dahlke; N Ghali; I Iesalnieks; M Loss; F Popp; P von Breitenbuch; A Agha; S A Lang; F Kullmann; H J Schlitt
Journal:  Int J Colorectal Dis       Date:  2007-04-26       Impact factor: 2.571

Review 8.  Cytoreductive Surgery plus HIPEC for Peritoneal Metastases from Colorectal Cancer.

Authors:  Aditi Bhatt; Diane Goéré
Journal:  Indian J Surg Oncol       Date:  2016-02-04

9.  Surgical cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis arising from the appendix.

Authors:  Lucas Sideris; Andrew Mitchell; Pierre Drolet; Guy Leblanc; Yves E Leclerc; Pierre Dubé
Journal:  Can J Surg       Date:  2009-04       Impact factor: 2.089

Review 10.  Using pharmacologic data to plan clinical treatments for patients with peritoneal surface malignancy.

Authors:  Kurt Van der Speeten; Oswald Anthony Stuart; Paul H Sugarbaker
Journal:  Curr Drug Discov Technol       Date:  2009-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.